{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:43:08Z","timestamp":1792806188047,"version":"4.5.0"},"reference-count":164,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Council for Scientific and Technological Development (CNPq), the Ministry of Science and Technology of Brazil","award":["317118\/2021-8"],"award-info":[{"award-number":["317118\/2021-8"]}],"id":[{"id":"https:\/\/ror.org\/03swz6y49","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Council for Scientific and Technological Development (CNPq), the Ministry of Science and Technology of Brazil","award":["3 16704\/2021-0"],"award-info":[{"award-number":["3 16704\/2021-0"]}],"id":[{"id":"https:\/\/ror.org\/03swz6y49","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Council for Scientific and Technological Development (CNPq), the Ministry of Science and Technology of Brazil","award":["431776\/2016-4"],"award-info":[{"award-number":["431776\/2016-4"]}],"id":[{"id":"https:\/\/ror.org\/03swz6y49","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Council for Scientific and Technological Development (CNPq), the Ministry of Science and Technology of Brazil","award":["312910\/2020-7"],"award-info":[{"award-number":["312910\/2020-7"]}],"id":[{"id":"https:\/\/ror.org\/03swz6y49","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Council for Scientific and Technological Development (CNPq), the Ministry of Science and Technology of Brazil","award":["2022\/05252-7"],"award-info":[{"award-number":["2022\/05252-7"]}],"id":[{"id":"https:\/\/ror.org\/03swz6y49","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Science, Technology, and Innovation (MCTI), Brazil","award":["317118\/2021-8"],"award-info":[{"award-number":["317118\/2021-8"]}],"id":[{"id":"https:\/\/ror.org\/050zdnc69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Science, Technology, and Innovation (MCTI), Brazil","award":["3 16704\/2021-0"],"award-info":[{"award-number":["3 16704\/2021-0"]}],"id":[{"id":"https:\/\/ror.org\/050zdnc69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Science, Technology, and Innovation (MCTI), Brazil","award":["431776\/2016-4"],"award-info":[{"award-number":["431776\/2016-4"]}],"id":[{"id":"https:\/\/ror.org\/050zdnc69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Science, Technology, and Innovation (MCTI), Brazil","award":["312910\/2020-7"],"award-info":[{"award-number":["312910\/2020-7"]}],"id":[{"id":"https:\/\/ror.org\/050zdnc69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Science, Technology, and Innovation (MCTI), Brazil","award":["2022\/05252-7"],"award-info":[{"award-number":["2022\/05252-7"]}],"id":[{"id":"https:\/\/ror.org\/050zdnc69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"S\u00e3o Paulo Research Foundation (FAPESP)","award":["317118\/2021-8"],"award-info":[{"award-number":["317118\/2021-8"]}],"id":[{"id":"https:\/\/ror.org\/02ddkpn78","id-type":"ROR","asserted-by":"crossref"}]},{"name":"S\u00e3o Paulo Research Foundation (FAPESP)","award":["3 16704\/2021-0"],"award-info":[{"award-number":["3 16704\/2021-0"]}],"id":[{"id":"https:\/\/ror.org\/02ddkpn78","id-type":"ROR","asserted-by":"crossref"}]},{"name":"S\u00e3o Paulo Research Foundation (FAPESP)","award":["431776\/2016-4"],"award-info":[{"award-number":["431776\/2016-4"]}],"id":[{"id":"https:\/\/ror.org\/02ddkpn78","id-type":"ROR","asserted-by":"crossref"}]},{"name":"S\u00e3o Paulo Research Foundation (FAPESP)","award":["312910\/2020-7"],"award-info":[{"award-number":["312910\/2020-7"]}],"id":[{"id":"https:\/\/ror.org\/02ddkpn78","id-type":"ROR","asserted-by":"crossref"}]},{"name":"S\u00e3o Paulo Research Foundation (FAPESP)","award":["2022\/05252-7"],"award-info":[{"award-number":["2022\/05252-7"]}],"id":[{"id":"https:\/\/ror.org\/02ddkpn78","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Antifungal therapy, especially with the azoles, could promote the incidence of less susceptible isolates of Cryptococcus neoformans and C. gattii species complexes (SC), mostly in developing countries. Given that these species affect mostly the immunocompromised host, the infections are severe and difficult to treat. This review encompasses the following topics: 1. infecting species and their virulence, 2. treatment, 3. antifungal susceptibility methods and available categorical endpoints, 4. genetic mechanisms of resistance, 5. clinical resistance, 6. fluconazole minimal inhibitory concentrations (MICs), clinical outcome, 7. environmental influences, and 8. the relevance of host factors, including pharmacokinetic\/pharmacodynamic (PK\/PD) parameters, in predicting the clinical outcome to therapy. As of now, epidemiologic cutoff endpoints (ECVs\/ECOFFs) are the most reliable antifungal resistance detectors for these species, as only one clinical breakpoint (amphotericin B and C. neoformans VNI) is available.<\/jats:p>","DOI":"10.3390\/pathogens13020128","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T04:57:07Z","timestamp":1706504227000},"page":"128","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Antifungal Resistance in Cryptococcal Infections"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1335-8808","authenticated-orcid":false,"given":"Marcia S. C.","family":"Melhem","sequence":"first","affiliation":[{"name":"Graduate Program in Sciences, Secretary of Health, S\u00e3o Paulo 01246-002, SP, Brazil"},{"name":"Graduate Program in Infectious and Parasitic Diseases, Federal University of Mato Grosso do Sul, Campo Grande 79070-900, MS, Brazil"},{"name":"Graduate Program in Tropical Diseases, State University of S\u00e3o Paulo, Botucatu 18618-687, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5934-8613","authenticated-orcid":false,"given":"Diniz Pereira","family":"Leite J\u00fanior","sequence":"additional","affiliation":[{"name":"Graduate Program in Sciences, Secretary of Health, S\u00e3o Paulo 01246-002, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana P. F.","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Graduate Program in Infectious and Parasitic Diseases, Federal University of Mato Grosso do Sul, Campo Grande 79070-900, MS, Brazil"},{"name":"Pathology Division, Adolfo Lutz Institute, S\u00e3o Paulo 01246-002, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena Bronze","family":"Macioni","sequence":"additional","affiliation":[{"name":"Graduate Program in Sciences, Secretary of Health, S\u00e3o Paulo 01246-002, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidiane de","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Grupo Fleury Laboratories, S\u00e3o Paulo 04701-200, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisandra Siufi","family":"de Ara\u00fajo","sequence":"additional","affiliation":[{"name":"Graduate Program in Infectious and Parasitic Diseases, Federal University of Mato Grosso do Sul, Campo Grande 79070-900, MS, Brazil"},{"name":"Central Public Health Laboratory-LACEN, Mycology Unit, Adolfo Lutz Institut, S\u00e3o Paulo 01246-002, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3608-0503","authenticated-orcid":false,"given":"Wellington S.","family":"Fava","sequence":"additional","affiliation":[{"name":"Graduate Program in Infectious and Parasitic Diseases, Federal University of Mato Grosso do Sul, Campo Grande 79070-900, MS, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas X.","family":"Bonfietti","sequence":"additional","affiliation":[{"name":"Central Public Health Laboratory-LACEN, Mycology Unit, Adolfo Lutz Institut, S\u00e3o Paulo 01246-002, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8925-7712","authenticated-orcid":false,"given":"Anamaria M. M.","family":"Paniago","sequence":"additional","affiliation":[{"name":"Graduate Program in Infectious and Parasitic Diseases, Federal University of Mato Grosso do Sul, Campo Grande 79070-900, MS, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0035-2439","authenticated-orcid":false,"given":"James","family":"Venturini","sequence":"additional","affiliation":[{"name":"Graduate Program in Infectious and Parasitic Diseases, Federal University of Mato Grosso do Sul, Campo Grande 79070-900, MS, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Espinel-Ingroff","sequence":"additional","affiliation":[{"name":"Central Public Health Laboratory-LACEN, Campo Grande 79074-460, MS, Brazil"},{"name":"VCU Medical Center, Richmond, VA 23284, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s15010-022-01805-y","article-title":"COVID-19-Associated Cryptococcus Infection (CACI): A Review of Literature and Clinical Pearls","volume":"50","author":"Regalla","year":"2022","journal-title":"Infection"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e0013422","DOI":"10.1128\/msphere.00134-22","article-title":"Membrane Integrity Contributes to Resistance of Cryptococcus neoformans to the Cell Wall Inhibitor caspofungin","volume":"7","author":"Ragsdale","year":"2022","journal-title":"mSphere"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Chan, K.-S., Lai, C.-C., Yu, W.-L., and Chao, C.-M. (2022). COVID-19 Associated with Cryptococcosis: A New Challenge during the Pandemic. J. Fungi, 8.","DOI":"10.3390\/jof8101111"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S1473-3099(22)00499-6","article-title":"The Global Burden of HIV-Associated Cryptococcal Infection in Adults in 2020: A Modelling Analysis","volume":"22","author":"Rajasingham","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Montoya, M.C., Magwene, P.M., and Perfect, J.R. (2021). Associations between Cryptococcus Genotypes, Phenotypes, and Clinical Parameters of Human Disease: A Review. J. Fungi, 7.","DOI":"10.3390\/jof7040260"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e02708-21","DOI":"10.1128\/mBio.02708-21","article-title":"Cryptococcus gattii Species Complex as an Opportunistic Pathogen: Underlying Medical Conditions Associated with the Infection","volume":"12","author":"Yang","year":"2021","journal-title":"mBio"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1007\/s10875-022-01341-2","article-title":"Cryptococcus gattii Infection as the Major Clinical Manifestation in Patients with Autoantibodies Against Granulocyte-Macrophage Colony-Stimulating Factor","volume":"42","author":"Wang","year":"2022","journal-title":"J. Clin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/cid\/ciab268","article-title":"MSG07: An International Cohort Study Comparing Epidemiology and Outcomes of Patients with Cryptococcus neoformans or Cryptococcus gattii Infections","volume":"73","author":"Baddley","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1086\/507897","article-title":"Cryptococcus gattii Infection: Characteristics and Epidemiology of Cases Identified in a South African Province with High HIV Seroprevalence, 2002\u20132004","volume":"43","author":"Morgan","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"17258","DOI":"10.1073\/pnas.0402981101","article-title":"A Rare Genotype of Cryptococcus gattii Caused the Cryptococcosis Outbreak on Vancouver Island (British Columbia, Canada)","volume":"101","author":"Kidd","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.fgb.2007.12.004","article-title":"Six Monophyletic Lineages Identified within Cryptococcus neoformans and Cryptococcus gattii by Multi-Locus Sequence Typing","volume":"45","author":"Bovers","year":"2008","journal-title":"Fungal Genet. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3201\/eid1810.120068","article-title":"Autochthonous and Dormant Cryptococcus gattii Infections in Europe","volume":"18","author":"Hagen","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.fgb.2015.02.009","article-title":"Recognition of Seven Species in the Cryptococcus gattii\/Cryptococcus neoformans Species Complex","volume":"78","author":"Hagen","year":"2015","journal-title":"Fungal Genet. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Okagaki, L.H., Strain, A.K., Nielsen, J.N., Charlier, C., Baltes, N.J., Chr\u00e9tien, F., Heitman, J., Dromer, F., and Nielsen, K. (2010). Cryptococcal Cell Morphology Affects Host Cell Interactions and Pathogenicity. PLoS Pathog., 6.","DOI":"10.1371\/annotation\/1b59fd9e-9ac9-4ea8-a083-14c413c80b03"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e00455-13","DOI":"10.1128\/mBio.00455-13","article-title":"Old Cryptococcus neoformans Cells Contribute to Virulence in Chronic Cryptococcosis","volume":"4","author":"Bouklas","year":"2013","journal-title":"mBio"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1469-0691.2010.03222.x","article-title":"Global VGIIa Isolates are of Comparable Virulence to the Major Fatal Cryptococcus gattii Vancouver Island Outbreak Genotype","volume":"17","author":"Ngamskulrungroj","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e02016-18","DOI":"10.1128\/mBio.02016-18","article-title":"Phenotypic Variability Correlates with Clinical Outcome in Cryptococcus Isolates Obtained from Botswanan HIV\/AIDS Patients","volume":"9","author":"Fernandes","year":"2018","journal-title":"mBio"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11046-017-0214-9","article-title":"Molecular Characterization and Antifungal Susceptibility Testing of Sequentially Obtained Clinical Cryptococcus deneoformans and Cryptococcus neoformans Isolates from Ljubljana, Slovenia","volume":"183","author":"Tomazin","year":"2018","journal-title":"Mycopathologia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s100960100549","article-title":"Evidence of Microevolution in a Clinical Case of Recurrent Cryptococcus neoformans Meningoencephalitis","volume":"20","author":"Blasi","year":"2001","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kassi, F.K., Drakulovski, P., Bellet, V., Roger, F., Chabrol, A., Krasteva, D., Doumbia, A., Landman, R., Kakou, A., and Reynes, J. (2019). Cryptococcus Genetic Diversity and Mixed Infections in Ivorian HIV Patients: A Follow up Study. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007812"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/myc.12171","article-title":"Molecular Epidemiology and Antifungal Susceptibility of Serbian Cryptococcus neoformans Isolates","volume":"57","author":"Pekmezovic","year":"2014","journal-title":"Mycoses"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1128\/jcm.34.7.1739-1744.1996","article-title":"Persistence, Replacement, and Microevolution of Cryptococcus neoformans Strains in Recurrent Meningitis in AIDS Patients","volume":"34","author":"Sullivan","year":"1996","journal-title":"J. Clin. Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Illnait-Zaragoz\u00ed, M.T., Mart\u00ednez-Mach\u00edn, G.F., Fern\u00e1ndez-Andreu, C.M., Hagen, F., Boekhout, T., Klaassen, C.H., and Meis, J.F. (2010). Microsatellite Typing and Susceptibilities of Serial Cryptococcus neoformans Isolates from Cuban Patients with Recurrent Cryptococcal Meningitis. BMC Infect. Dis., 10.","DOI":"10.1186\/1471-2334-10-289"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Martho, K.F.C., de Melo, A.T., Takahashi, J.P.F., Guerra, J.M., Santos, D.C.d.S., Purisco, S.U., Melhem, M.d.S.C., Fazioli, R.d.A., Phanord, C., and Sartorelli, P. (2016). Amino Acid Permeases and Virulence in Cryptococcus neoformans. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163919"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1080\/21505594.2018.1431087","article-title":"The Capsule of Cryptococcus neoformans","volume":"10","author":"Casadevall","year":"2019","journal-title":"Virulence"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1111\/j.1462-5822.2008.01186.x","article-title":"Capsule Enlargement in Cryptococcus neoformans Confers Resistance to Oxidative Stress Suggesting a Mechanism for Intracellular Survival","volume":"10","author":"Zaragoza","year":"2008","journal-title":"Cell. Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1099\/jmm.0.036152-0","article-title":"Influence of Capsule Size on the in Vitro Activity of Antifungal Agents against Clinical Cryptococcus neoformans var","volume":"61","author":"Vitale","year":"2012","journal-title":"grubii Strains. J. Med. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1128\/iai.63.8.3131-3136.1995","article-title":"Cryptococcus neoformans Melanin and Virulence: Mechanism of Action","volume":"63","author":"Wang","year":"1995","journal-title":"Infect. Immun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/13693780412331271081","article-title":"Effect of Melanization upon Porosity of the Cryptococcal Cell Wall","volume":"43","author":"Jacobson","year":"2005","journal-title":"Med. Mycol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.mmcr.2014.11.002","article-title":"Report of Filamentous Forms in a Mating Type VNI Clinical Sequential Isolates of Cryptococcus neoformans from an HIV Virus-Infected Patient","volume":"7","author":"Martins","year":"2015","journal-title":"Med. Mycol. Case Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0966-842X(00)88957-X","article-title":"Virulence factors of Cryptococcus neoformans","volume":"3","author":"Kozel","year":"1995","journal-title":"Trends Microbiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1080\/21505594.2019.1614383","article-title":"Basic principles of the virulence of Cryptococcus","volume":"10","author":"Zaragoza","year":"2019","journal-title":"Virulence"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41579-022-00796-9","article-title":"Architecture of the Dynamic Fungal Cell Wall","volume":"21","author":"Gow","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e00196-12","DOI":"10.1128\/mBio.00196-12","article-title":"Cryptococcal Genotype Influences Immunologic Response and Human Clinical Outcome After Meningitis","volume":"3","author":"Wiesner","year":"2012","journal-title":"mBio"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Birkenfeld, Z.M., Dittel, N., Harrer, T., Stephan, C., Kiderlen, A.F., and Rickerts, V. (2022). Phenotypic Diversity of Cryptococcus neoformans var. neoformans Clinical Isolates from Localized and Disseminated Infections. Microorganisms, 10.","DOI":"10.3390\/microorganisms10020321"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Altamirano, S., Jackson, K.M., and Nielsen, K. (2020). The Interplay of Phenotype and Genotype in Cryptococcus neoformans Disease. Biosci. Rep., 40.","DOI":"10.1042\/BSR20190337"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Del Poeta, M., Wormley, F.L., and Lin, X. (2023). Host populations, challenges, and commercialization of cryptococcal vaccines. PLoS Pathog., 19.","DOI":"10.1371\/journal.ppat.1011115"},{"key":"ref_38","unstructured":"World Health Organization (2022). Guidelines for Diagnosing, Preventing and Managing Cryptococcal Disease Among Adults, Adolescents and Children Living with HIV [Internet], World Health Organization."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa1110404","article-title":"Combination Antifungal Therapy for Cryptococcal Meningitis","volume":"368","author":"Day","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1710922","article-title":"Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa","volume":"378","author":"Molloy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue Penetration of Antifungal Agents","volume":"27","author":"Felton","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1128\/AAC.00034-11","article-title":"Correlation of Susceptibility of Cryptococcus neoformans to Amphotericin B with Clinical Outcome","volume":"55","author":"Larsen","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/myc.1990.33.7-8.369","article-title":"Persistence of Cryptococcus neoformans in Seminal Fluid and Urine under Itraconazole Treatment. The Urogenital Tract (Prostate) as a Niche for Cryptococcus neoformans","volume":"33","author":"Staib","year":"1990","journal-title":"Mycoses"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1128\/AAC.39.2.553","article-title":"Fluconazole Penetration into the Human Prostate","volume":"39","author":"Finley","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1128\/AAC.37.6.1270","article-title":"Pharmacokinetics of 18F-Labeled Fluconazole in Healthy Human Subjects by Positron Emission Tomography","volume":"37","author":"Fischman","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","first-page":"454","article-title":"Treatment strategies for cryptococcal infections: Challenges, advances and future outlook","volume":"19","author":"Iyer","year":"2021","journal-title":"Microbiol. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7326\/0003-4819-104-2-234","article-title":"Cryptococcal Disease in Patients with the acquired immunodeficiency syndrome. Diagnostic Features and Outcome of Treatment","volume":"104","author":"Zuger","year":"1986","journal-title":"Ann. Intern. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nchembio.1496","article-title":"Amphotericin Forms an Extramembranous and Fungicidal Sterol Sponge","volume":"10","author":"Anderson","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tim.2010.02.004","article-title":"Therapy for Fungal Diseases: Opportunities and Priorities","volume":"18","author":"Denning","year":"2010","journal-title":"Trends Microbiol."},{"key":"ref_51","unstructured":"EUCAST (2023, December 12). The European Committee on Antimicrobial Susceptibility Testing. Overview of antifungal ECOFFs and clinical breakpoints for yeasts, moulds and dermatophytes using the EUCAST E.Def 7.4, E.Def 9.4 and E.Def 11.0 procedures. Version 4.0, 2023. Available online: http:\/\/www.eucast.org."},{"key":"ref_52","unstructured":"CLSI M57S (2022). Principles and Procedures for the Development of Epidemiological Cutoff Values for Antifungal Susceptibility Testing, Clinical and Laboratory Standards Institute."},{"key":"ref_53","unstructured":"CLSI (2022). Epidemiological Cutoff Values for Antifungal Susceptibility Testing, Clinical and Laboratory Standards Institute. [4th ed.]. CLSI Supplement M59S."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/AAC.44.6.1544-1548.2000","article-title":"Correlation of Fluconazole MICs with Clinical Outcome in Cryptococcal Infection","volume":"44","author":"Aller","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1128\/AAC.01520-05","article-title":"Results Obtained with Various Antifungal Susceptibility Testing Methods Do Not Predict Early Clinical Outcome in Patients with Cryptococcosis","volume":"50","author":"Dannaoui","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1128\/AAC.39.7.1526","article-title":"Cross-Resistance to Polyene and Azole Drugs in Cryptococcus neoformans","volume":"39","author":"Hollomon","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1054\/drup.1999.0090","article-title":"Drug Resistance in Cryptococcus Neoformans","volume":"2","author":"Perfect","year":"1999","journal-title":"Drug Resist. Updates"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/clinids\/22.2.322","article-title":"Identification of Patients with Acute AIDS-Associated Cryptococcal Meningitis Who Can Be Effectively Treated with Fluconazole: The Role of Antifungal Susceptibility Testing","volume":"22","author":"Witt","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/13693786.2012.715763","article-title":"Fluconazole Resistance in Cryptococcal Disease: Emerging or Intrinsic?","volume":"51","author":"Cheong","year":"2013","journal-title":"Med. Mycol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.riam.2009.02.001","article-title":"Fluconazole and Amphotericin B Susceptibility Testing of Cryptococcus neoformans: Results of Minimal Inhibitory Concentrations against 265 Isolates from HIV-Positive Patients before and after Two or More Months of Antifungal Therapy","volume":"26","author":"Arechavala","year":"2009","journal-title":"Rev. Iberoam. Micol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/infdis\/168.2.508","article-title":"Correlation of in Vitro Azole Susceptibility with in Vivo Response in a Murine Model of Cryptococcal Meningitis","volume":"168","author":"Velez","year":"1993","journal-title":"J. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Espinel-Ingroff, A., and Cant\u00f3n, E. (2023). Methods for Antifungal Susceptibility Testing of the Cryptococcus neoformans\/C. gattii Complex: Strengths and Limitations. J. Fungi, 9.","DOI":"10.3390\/jof9050542"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1128\/JCM.01187-06","article-title":"Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B","volume":"44","year":"2006","journal-title":"J. Clin. Microbiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/mmy\/myy150","article-title":"Comparative Antifungal Susceptibility Analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute Broth Microdilution Methods","volume":"57","author":"Nishikawa","year":"2019","journal-title":"Med. Mycol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"dlac033","DOI":"10.1093\/jacamr\/dlac033","article-title":"Molecular Mechanisms Underlying the Emergence of Polygenetic Antifungal Drug Resistance in Msh2 Mismatch Repair Mutants of Cryptococcus","volume":"4","author":"Albehaijani","year":"2022","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/jac\/dkac161","article-title":"Molecular Mechanisms of Acquired Antifungal Drug Resistance in Principal Fungal Pathogens and EUCAST Guidance for Their Laboratory Detection and Clinical Implications","volume":"77","author":"Rogers","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_67","unstructured":"Pfaller, M.A., Lodge, J.K., and Ghannoun, M.A. (2011). Cryptococcus from Human Pathogen to Model Yeast, ASM Press. [2nd ed.]."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1128\/IAI.74.2.1352-1359.2006","article-title":"Role of AFR1, an ABC Transporter-Encoding Gene, in the in Vivo Response to Fluconazole and Virulence of Cryptococcus neoformans","volume":"74","author":"Sanguinetti","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.imj.2022.08.006","article-title":"Advanced Approach for Antifungal Susceptibility and Characterization of Resistance Properties in Clinical and Environmental Isolates of Cryptococcus Species Complex","volume":"1","author":"Lahiri","year":"2022","journal-title":"Infect. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e01751-17","DOI":"10.1128\/AAC.01751-17","article-title":"Roles of Three Cryptococcus neoformans and Cryptococcus gattii Efflux Pump-Coding Genes in Response to Drug Treatment","volume":"62","author":"Chang","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Oliveira, N.K., Bhattacharya, S., Gambhir, R., Joshi, M., and Fries, B.C. (2022). Novel ABC Transporter Associated with Fluconazole Resistance in Aging of Cryptococcus neoformans. J. Fungi, 8.","DOI":"10.20944\/preprints202201.0263.v1"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Winski, C.J., Qian, Y., Mobashery, S., and Santiago-Tirado, F.H. (2022). An Atypical ABC Transporter Is Involved in Antifungal Resistance and Host Interactions in the Pathogenic Fungus Cryptococcus neoformans. mBio, 13.","DOI":"10.1128\/mbio.01539-22"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e01340-15","DOI":"10.1128\/mBio.01340-15","article-title":"Polyploid Titan Cells Produce Haploid and Aneuploid Progeny to Promote Stress Adaptation","volume":"6","author":"Gerstein","year":"2015","journal-title":"mBio"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e00731-18","DOI":"10.1128\/IAI.00731-18","article-title":"A Glucuronoxylomannan Epitope Exhibits Serotype-Specific Accessibility and Redistributes towards the Capsule Surface during Titanization of the Fungal Pathogen Cryptococcus neoformans","volume":"87","author":"Probert","year":"2019","journal-title":"Infect. Immun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1128\/MCB.21.9.3179-3191.2001","article-title":"Cyclic AMP-dependent protein kinase controls virulence of the fungal pathogen Cryptococcus neoformans","volume":"21","author":"Alspaugh","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Zaragoza, O., Garc\u00eda-Rodas, R., Nosanchuk, J.D., Cuenca-Estrella, M., Rodr\u00edguez-Tudela, J.L., and Casadevall, A. (2010). Fungal Cell Gigantism during Mammalian Infection. PLoS Pathog., 6.","DOI":"10.1371\/annotation\/0675044c-d80f-456f-bb63-4f85fb1d0c33"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1128\/EC.00121-12","article-title":"Titan Cells Confer Protection from Phagocytosis in Cryptococcus neoformans Infections","volume":"11","author":"Okagaki","year":"2012","journal-title":"Eukaryot. Cell"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.mib.2019.11.001","article-title":"A Titanic Drug Resistance Threat in Cryptococcus neoformans","volume":"52","author":"Zafar","year":"2019","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1128\/AAC.00295-09","article-title":"Heteroresistance to Fluconazole in Cryptococcus neoformans Is Intrinsic and Associated with Virulence","volume":"53","author":"Sionov","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1128\/AAC.00153-10","article-title":"Heteroresistance of Cryptococcus gattii to Fluconazole","volume":"54","author":"Varma","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/JCM.41.1.267-272.2003","article-title":"Characterization of Heteroresistance to Fluconazole among Clinical Isolates of Cryptococcus neoformans","volume":"41","author":"Yamazumi","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s12281-017-0298-1","article-title":"Heteroresistance to Fluconazol in Clinical and Environmental Brazilian Strains of Cryptococcus neoformans\/C. gattii Species Complex","volume":"11","author":"Feliciano","year":"2017","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e02575-19","DOI":"10.1128\/mBio.02575-19","article-title":"Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance","volume":"10","author":"Hope","year":"2019","journal-title":"mBio"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"myac005","DOI":"10.1093\/mmy\/myac005","article-title":"Investigation of Fluconazole Heteroresistance in Clinical and Environmental Isolates of Cryptococcus neoformans Complex and Cryptococcus gattii Complex in the State of Amazonas, Brazil","volume":"60","author":"Moreira","year":"2022","journal-title":"Med. Mycol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Sionov, E., Lee, H., Chang, Y.C., and Kwon-Chung, K.J. (2010). Cryptococcus neoformans Overcomes Stress of Azole Drugs by Formation of Disomy in Specific Multiple Chromosomes. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1000848"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Ngamskulrungroj, P., Chang, Y., Hansen, B., Bugge, C., Fischer, E., and Kwon-Chung, K.J. (2012). Characterization of the chromosome 4 genes that affect fluconazole-induced disomy formation in Cryptococcus neoformans. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033022"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1172\/JCI124516","article-title":"Dynamic Ploidy Changes Drive Fluconazole Resistance in Human Cryptococcal Meningitis","volume":"29","author":"Stone","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e2338","DOI":"10.1093\/cid\/ciaa1544","article-title":"Antifungal Susceptibility Does Not Correlate With Fungal Clearance or Survival in AIDS-Associated Cryptococcal Meningitis","volume":"73","author":"Chau","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_89","first-page":"795","article-title":"Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with\/without fluconazole prophylaxis","volume":"89","author":"Manosuthi","year":"2006","journal-title":"J. Med. Assoc. Thai."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"ofw076","DOI":"10.1093\/ofid\/ofw076","article-title":"Retrospective Study of Cryptococcal Meningitis With Elevated Minimum Inhibitory Concentration to Fluconazole in Immunocompromised Patients","volume":"3","author":"Nasri","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.diagmicrobio.2012.01.014","article-title":"Role of Quantitative CSF Microscopy to Predict Culture Status and Outcome in HIV-Associated Cryptococcal Meningitis in a Brazilian Cohort","volume":"73","author":"Vidal","year":"2012","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bjid.2012.10.020","article-title":"Strategies to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis in Latin America","volume":"17","author":"Vidal","year":"2013","journal-title":"Braz J Infect Dis."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"de Oliveira, L., Melhem, M.d.S.C., Buccheri, R., Chagas, O.J., Vidal, J.E., and Diaz-Quijano, F.A. (2022). Early Clinical and Microbiological Predictors of Outcome in Hospitalized Patients with Cryptococcal Meningitis. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07118-7"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1086\/515074","article-title":"Early Mycological Treatment Failure in AIDS-Associated Cryptococcal Meningitis","volume":"28","author":"Robinson","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/604716","article-title":"Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV-Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 Patients","volume":"49","author":"Bicanic","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40249-023-01073-4","article-title":"Cryptococcus neoformans, a global threat to human health","volume":"17","author":"Zhao","year":"2023","journal-title":"Infect. Dis. Poverty"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s40265-022-01757-5","article-title":"Treatment of Cryptococcal Meningitis: How Have We Got Here and Where Are We Going?","volume":"82","author":"Ngan","year":"2022","journal-title":"Drugs"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"myad011","DOI":"10.1093\/mmy\/myad011","article-title":"Characteristics, mortality, associated variables with death, and therapeutic response among HIV-positive, solid organ transplant (SOT), and non-HIV-positive\/non-transplant (NHNT) patients with cryptococcosis: First multicenter cohort study in Brazil","volume":"61","author":"Vidal","year":"2023","journal-title":"Med. Mycol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/clinids\/19.5.975-a","article-title":"Increased Fluconazole Resistance of Cryptococcus neoformans Isolated from a Patient with AIDS and Recurrent Meningitis","volume":"19","author":"Paugam","year":"1994","journal-title":"Clin. Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1086\/524071","article-title":"Antimicrobial Resistance: Resistance to Antifungal Agents: Mechanisms and Clinical Impact","volume":"46","author":"Kanafani","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1590\/s1678-9946201759049","article-title":"Cryptococcus neoformans and C. gattii Isolates from Both HIV-Infected and Uninfected Patients: Antifungal Susceptibility and Outcome of Cryptococcal Disease","volume":"59","author":"Nascimento","year":"2017","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"ofz369","DOI":"10.1093\/ofid\/ofz369","article-title":"Minimum Inhibitory Concentration Distributions of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model","volume":"6","author":"Chesdachai","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1128\/AAC.06252-11","article-title":"Cryptococcus neoformans-Cryptococcus gattii Species Complex: An International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Amphotericin B and Flucytosine","volume":"56","author":"Chowdhary","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1128\/AAC.01115-12","article-title":"Cryptococcus neoformans-Cryptococcus gattii Species Complex: An International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole","volume":"56","author":"Aller","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1128\/AAC.00048-11","article-title":"Trends in Antifungal Drug Susceptibility of Cryptococcus neoformans Isolates Obtained through Population-Based Surveillance in South Africa in 2002\u20132003 and 2007\u20132008","volume":"55","author":"Govender","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev.micro.60.080805.142102","article-title":"The Biology of the Cryptococcus neoformans Species Complex","volume":"60","author":"Lin","year":"2006","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/clinids\/20.3.611","article-title":"Cryptococcal Disease of the CNS in Immunocompetent Hosts: Influence of Cryptococcal Variety on Clinical Manifestations and Outcome","volume":"20","author":"Mitchell","year":"1995","journal-title":"Clin. Infect. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/clinids\/21.1.28","article-title":"Clinical and Host Differences between Infections with the Two Varieties of Cryptococcus neoformans","volume":"21","author":"Speed","year":"1995","journal-title":"Clin. Infect. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Hagen, F., Ceresini, P.C., Polacheck, I., Ma, H., van Nieuwerburgh, F., Gabald\u00f3n, T., Kagan, S., Pursall, E.R., Hoogveld, H.L., and van Iersel, L.J.J. (2013). Ancient Dispersal of the Human Fungal Pathogen Cryptococcus gattii from the Amazon Rainforest. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0071148"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3109\/13693786.2011.602126","article-title":"Correlation of Antifungal Susceptibility and Molecular Type within the Cryptococcus neoformans \/ C. gattii Species Complex","volume":"50","author":"Trilles","year":"2012","journal-title":"Med. Mycol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.cmi.2020.06.007","article-title":"How to Interpret MICs of Antifungal Compounds According to the Revised Clinical Breakpoints v. 10.0 European Committee on Antimicrobial Susceptibility Testing (EUCAST)","volume":"26","author":"Arendrup","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/myc.12847","article-title":"Fluconazole Resistance Is Not a Predictor of Poor Outcome in Patients with Cryptococcosis","volume":"62","author":"Vena","year":"2018","journal-title":"Mycoses"},{"key":"ref_113","unstructured":"CLSI (2022). Performance Starndards for Antifugal Susceptibility Testinf of Yeasts, Clinical Laboratory Standards Institute. [3rd ed.]. CLSI Supplement M27M44S."},{"key":"ref_114","unstructured":"(2023, December 12). EUCAST Definitive Document E.Def 7.4 Method for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Yeasts. EUCAST E.Def 7.4. Available online: https:\/\/www.eucast.org\/astoffungi\/methodsinantifungalsusceptibilitytesting\/susceptibility_testing_of_yeasts."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/clinids\/22.2.329","article-title":"Editorial Response: Management of Cryptococcal Meningitis\u2014Have We Answered All the Questions?","volume":"22","author":"Powderly","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.1128\/AAC.01299-15","article-title":"Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda","volume":"59","author":"Smith","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1128\/AAC.00742-06","article-title":"In Vitro-Clinical Correlations for Amphotericin B Susceptibility in AIDS-Associated Cryptococcal Meningitis","volume":"51","author":"Larsen","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Wu, T.S., Lin, J.F., Cheng, C.W., Huang, P.Y., and Yang, J.H. (2023). Lack of Association between YEASTONE Antifungal Susceptibility Tests and Clinical Outcomes of Cryptococcus Meningitis. J Fungi., 10.","DOI":"10.3390\/jof9020232"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1128\/JCM.43.5.2163-2167.2005","article-title":"Global Trends in the Antifungal Susceptibility of Cryptococcus neoformans (1990 to 2004)","volume":"43","author":"Pfaller","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s10096-004-1136-2","article-title":"In Vitro Activity of Amphotericin B, Fluconazole and Voriconazole against 162 Cryptococcus neoformans Isolates from Africa and Cambodia","volume":"23","author":"Chandenier","year":"2004","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1128\/AAC.45.11.3065-3069.2001","article-title":"Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998","volume":"45","author":"Brandt","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1128\/AAC.00746-10","article-title":"In Vitro Antifungal Susceptibilities and Amplified Fragment Length Polymorphism Genotyping of a Worldwide Collection of 350 Clinical, Veterinary, and Environmental Cryptococcus gattii Isolates","volume":"54","author":"Hagen","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_123","first-page":"82","article-title":"Genotypes and in vitro antifungal susceptibility of Cryptococcus isolates in Sichuan Province","volume":"46","author":"Lei","year":"2015","journal-title":"J. Sichuan Univ. Med. Sci. Ed."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/jac\/dki393","article-title":"Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var","volume":"56","author":"Perkins","year":"2005","journal-title":"neoformans. J. Antimicrob. Chemother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1469-0691.2008.02021.x","article-title":"In Vitro Susceptibility of Cryptococcus gattii Clinical Isolates","volume":"14","author":"Zaragoza","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_126","first-page":"324","article-title":"In Vitro Susceptibilities of Malaysian Clinical Isolates of Cryptococcus neoformans var","volume":"49","author":"Tay","year":"2006","journal-title":"grubii and Cryptococcus gattii to Five Antifungal Drugs. Mycoses"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11046-015-9871-8","article-title":"Comparison of Different In Vitro Tests to Detect Cryptococcus neoformans Not Susceptible to Amphotericin B","volume":"179","author":"Vivot","year":"2015","journal-title":"Mycopathologia"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/jac\/42.2.217","article-title":"In-Vitro Susceptibility of Cryptococcus neoformans Isolates to Fluconazole and Itraconazole","volume":"42","author":"Davey","year":"1998","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1128\/JCM.36.10.2874-2876.1998","article-title":"Fluconazole Susceptibility Testing of Cryptococcus neoformans: Comparison of Two Broth Microdilution Methods and Clinical Correlates among Isolates from Ugandan AIDS Patients","volume":"36","author":"Jessup","year":"1998","journal-title":"J. Clin. Microbiol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/myc.12747","article-title":"A Systematic Review of Fluconazole Resistance in Clinical Isolates of Cryptococcus Species","volume":"61","author":"Bongomin","year":"2018","journal-title":"Mycoses"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/507895","article-title":"Symptomatic Relapse of HIV-Associated Cryptococcal Meningitis after Initial Fluconazole Monotherapy: The Role of Fluconazole Resistance and Immune Reconstitution","volume":"43","author":"Bicanic","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/jac\/dkh361","article-title":"Increasing in Vitro Resistance to Fluconazole in Cryptococcus neoformans Cambodian Isolates: April 2000 to March 2002","volume":"54","author":"Sar","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1439-0507.2007.01478.x","article-title":"Current Scenario of Cryptococcosis and Antifungal Susceptibility Pattern in India: A Cause for Reappraisal","volume":"51","author":"Capoor","year":"2008","journal-title":"Mycoses"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Chen, Y.-C., Chang, T.-Y., Liu, J.-W., Chen, F.-J., Chien, C.-C., Lee, C.-H., and Lu, C.-H. (2015). Increasing Trend of Fluconazole-Non-Susceptible Cryptococcus neoformans in Patients with Invasive Cryptococcosis: A 12-Year Longitudinal Study. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-1023-8"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2147\/IDR.S235473","article-title":"Cryptococcus neoformans\/gattii Species Complexes from Pre-HIV Pandemic Era Contain Unusually High Rate of Non-Wild-Type Isolates for Amphotericin B","volume":"13","author":"Pharkjaksu","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/095646249500600510","article-title":"Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis","volume":"6","author":"Birley","year":"1995","journal-title":"Int. J. STD AIDS"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/jac\/dkg399","article-title":"Fluconazole and Itraconazole Susceptibility of Clinical Isolates of Cryptococcus neoformans at a Tertiary Care Centre in India: A Need for Care","volume":"52","author":"Datta","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1099\/jmm.0.029025-0","article-title":"In Vitro Antifungal Susceptibility Profiles and Genotypes of 308 Clinical and Environmental Isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii Serotype B from North-Western India","volume":"60","author":"Chowdhary","year":"2011","journal-title":"J. Med. Microbiol."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Lee, C.-H., Chang, T.-Y., Liu, J.-W., Chen, F.-J., Chien, C.-C., Tang, Y.-F., and Lu, C.-H. (2012). Correlation of Anti-Fungal Susceptibility with Clinical Outcomes in Patients with Cryptococcal Meningitis. BMC Infect. Dis., 12.","DOI":"10.1186\/1471-2334-12-361"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1128\/AAC.37.6.1383","article-title":"Susceptibilities of Serial Cryptococcus neoformans Isolates from Patients with Recurrent Cryptococcal Meningitis to Amphotericin B and Fluconazole","volume":"37","author":"Casadevall","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jac\/25.1.175","article-title":"Predictive value of susceptibility tests for the outcome of antibacterial therapy","volume":"25","author":"Lorian","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_142","first-page":"675213","article-title":"Global Molecular Epidemiology of Cryptococcus neoformans and Cryptococcus gattii: An Atlas of the Molecular Types","volume":"2013","author":"Cogliati","year":"2013","journal-title":"Scientifica (Cairo)."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/jac\/dkm192","article-title":"Antifungal Susceptibility of Cryptococcus neoformans and Cryptococcus gattii Isolates from Decayed Wood of Trunk Hollows of Ficus Religiosa and Syzygium Cumini Trees in North-Western India","volume":"60","author":"Khan","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1590\/0037-8682-0025-2013","article-title":"Environmental Isolation, Biochemical Identification, and Antifungal Drug Susceptibility of Cryptococcus Species","volume":"46","author":"Teodoro","year":"2013","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1590\/S1517-838246420140564","article-title":"Antifungal Susceptibility of Clinical and Environmental Cryptococcus neoformans and Cryptococcus gattii Isolates in Jabalpur, a City of Madhya Pradesh in Central India","volume":"46","author":"Gutch","year":"2015","journal-title":"Braz. J. Microbiol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1439-0507.2008.01662.x","article-title":"Molecular Typing and Antifungal Susceptibility of Clinical and Environmental Cryptococcus neoformans Species Complex Isolates in Goiania, Brazil","volume":"53","author":"Souza","year":"2010","journal-title":"Mycoses"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.diagmicrobio.2011.11.016","article-title":"Susceptibility to Antifungal Agents and Genotypes of Brazilian Clinical and Environmental Cryptococcus gattii Strains","volume":"72","author":"Silva","year":"2012","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1590\/S0036-46652005000100006","article-title":"Environmental Strains of Cryptococcus neoformans variety grubii in the City of Santos, SP, Brazil","volume":"47","author":"Soares","year":"2005","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Pllana-Hajdari, D., Cogliati, M., \u010ci\u010dmak, L., Ple\u0161ko, S., Mlinari\u0107-Missoni, E., and Marekovi\u0107, I. (2019). First Isolation, Antifungal Susceptibility, and Molecular Characterization of Cryptococcus neoformans from the Environment in Croatia. J. Fungi, 5.","DOI":"10.3390\/jof5040099"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11046-009-9245-1","article-title":"Urban Pigeons (Columba Livia) as a Potential Source of Pathogenic Yeasts: A Focus on Antifungal Susceptibility of Cryptococcus Strains in Northeast Brazil","volume":"169","author":"Costa","year":"2010","journal-title":"Mycopathologia"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Florek, M., Korzeniowska-Kowal, A., Wzorek, A., W\u0142odarczyk, K., Marynowska, M., Pogorzelska, A., Brodala, M., Ploch, S., Buczek, D., and Balon, K. (2021). Prevalence, Genetic Structure, and Antifungal Susceptibility of the Cryptococcus neoformans\/C. gattii Species Complex Strains Collected from the Arboreal Niche in Poland. Pathogens, 11.","DOI":"10.3390\/pathogens11010008"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3314\/mmj.54.303","article-title":"Prevalence and Antifungal Susceptibility of Cryptococcus neoformans Isolated from Pigeon Excreta in Chon Buri Province, Eastern Thailand","volume":"54","author":"Tangwattanachuleeporn","year":"2013","journal-title":"Med. Mycol. J."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1128\/AAC.01384-07","article-title":"In Vitro Activity of the New Azole Isavuconazole (BAL4815) Compared with Six Other Antifungal Agents against 162 Cryptococcus neoformans Isolates from Cuba","volume":"52","author":"Boekhout","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Carlson, T., Lupinacci, E., Moseley, K., and Chandrasekaran, S. (2021). Effects of Environmental Factors on Sensitivity of Cryptococcus neoformans to Fluconazole and Amphotericin B. FEMS Microbiol. Lett., 368.","DOI":"10.1093\/femsle\/fnab040"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.scitotenv.2019.05.094","article-title":"From the Environment to the Host: How Non-Azole Agrochemical Exposure Affects the Antifungal Susceptibility and Virulence of Cryptococcus gattii","volume":"681","author":"Bastos","year":"2019","journal-title":"Sci. Total Environ."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Bastos, R.W., Rossato, L., Goldman, G.H., and Santos, D.A. (2021). Fungicide Effects on Human Fungal Pathogens: Cross-Resistance to Medical Drugs and Beyond. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1010073"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e01179-17","DOI":"10.1128\/AAC.01179-17","article-title":"Environmental Triazole Induces Cross-Resistance to Clinical Drugs and Affects Morphophysiology and Virulence of Cryptococcus gattii and C. neoformans","volume":"62","author":"Bastos","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12281-020-00373-8","article-title":"Could Fungicides Lead to Azole Drug Resistance in a Cross-Resistance Manner among Environmental Cryptococcus Strains?","volume":"14","author":"Takahashi","year":"2020","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/mmi.14565","article-title":"Combatting the Evolution of Antifungal Resistance in Cryptococcus neoformans","volume":"114","author":"Bermas","year":"2020","journal-title":"Mol. Microbiol."},{"key":"ref_160","unstructured":"EUCAST (2023, December 12). ESCMID New Definitions of S, I and R from 2019. Available online: https:\/\/www.eucast.org\/newsiandr\/."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11095-018-2402-9","article-title":"Population Pharmacokinetic Modeling to Describe the Total Plasma and Free Brain Levels of Fluconazole in Healthy and Cryptococcus neoformans Infected Rats: How Does the Infection Impact the Drug\u2019s Levels on Biophase?","volume":"35","author":"Alves","year":"2018","journal-title":"Pharm. Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(04)16301-0","article-title":"Combination antifungal therapies for HIV-associated cryptococcal meningitis: A randomised trial","volume":"363","author":"Brouwer","year":"2004","journal-title":"Lancet"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1128\/AAC.00216-13","article-title":"Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and In Vitro Susceptibility Breakpoints","volume":"57","author":"Sudan","year":"2013","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/2\/128\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:50:59Z","timestamp":1760104259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/2\/128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":164,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["pathogens13020128"],"URL":"https:\/\/doi.org\/10.3390\/pathogens13020128","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]}}}